Filing Details

Accession Number:
0001415889-24-015676
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-05 19:23:19
Reporting Period:
2024-06-03
Accepted Time:
2024-06-05 19:23:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1817713 Janux Therapeutics Inc. JANX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1760431 Tighe Reardon C/O Janux Therapeutics, Inc.
10955 Vista Sorrento Parkway, Suite 200
San Diego CA 92130
Acting Chief Financial Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-06-03 131,196 $54.75 633,673 No 4 S Indirect By Avalon BioVentures I, LP
Common Stock Disposition 2024-06-03 691,525 $54.75 3,340,018 No 4 S Indirect By Avalon BioVentures SPV I, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Avalon BioVentures I, LP
No 4 S Indirect By Avalon BioVentures SPV I, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 174,989 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
  3. The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
  4. The shares held directly by the Reporting Person prior to the transactions reported herein reflect the receipt of shares pursuant to the pro rata distributions in kind, effected by each of ABV I and ABV SPV to its general partner and limited partners for no additional consideration, and the further pro rata distribution in kind by the general partners of ABV I and ABV SPV, for no additional consideration to their members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership from indirect to direct, which was exempt from reporting pursuant to Rule 16a-13.